On April 4th, CBD manufacturer Ispire went public on the NASDAQ Stock Exchange in the United States, issuing 2.7 million common shares at a price of $7.00 per share.
Laihe Biotech is a domestic enterprise in the plant extract industry, primarily engaged in the research and development, production, and sales of standardized plant extracts and high-purity active monomers.
The vaporization industry is an important downstream application area of industrial hemp. According to research data from Frost Sullivan, the global market size for electronic vaporization devices is expected to have an annual growth rate of 18.1% from 2018 to 2022 and is anticipated to maintain a growth rate of around 18.5% from 2022 to 2027.
Rhein Biotech has obtained the first public offering of shares by Ispire for distribution.
On April 7th, RAINBIO (Rhenium Biotech) released an announcement stating that the company used its own funds to acquire 214,285 shares of Ispire's (stock symbol "ISPR") initial public offering on the NASDAQ at a price of $7.00 per share, totaling $1,499,995. These newly issued shares became available for trading on the NASDAQ on April 4th, 2023.
Favorable for collaboration in the marijuana industry.
Rhine Biotech has announced its participation in Ispire's IPO strategic placement to deepen cooperation between the two companies in the industrial cannabis business. By combining their respective sales channels and resources, the companies hope to achieve mutually beneficial cooperation.
On its first day of trading, Ispire closed at $7.55, representing a 7.86% increase and a market capitalization of $400 million. As of now, the latest stock price is $7.00, and the latest market capitalization is $368.7 million.
Related Reading:
CBD manufacturer Ispire has successfully completed its initial public offering (IPO), raising a total of $18.9 million in funds.
CBD manufacturer Ispire has announced the pricing for its initial public offering (IPO): $7 per share for the issuance of 2.7 million shares.
References:
Rhine Biotech: Announcement Regarding the Acquisition of Shares Offered for Public Sale by Ispire and Initial Listing.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
